{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T04:16:00Z","timestamp":1743480960153,"version":"3.40.3"},"reference-count":46,"publisher":"Informa UK Limited","issue":"4","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Drug Development and Industrial Pharmacy"],"published-print":{"date-parts":[[2025,4,3]]},"DOI":"10.1080\/03639045.2025.2473505","type":"journal-article","created":{"date-parts":[[2025,3,4]],"date-time":"2025-03-04T02:09:27Z","timestamp":1741054167000},"page":"365-374","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":0,"title":["A novel synthetic approach for the piperazynyl pyrimidine intermediate: focus on the cost cutting of buspirone drug at commercial level"],"prefix":"10.1080","volume":"51","author":[{"given":"Anjan Kumar","family":"Nayak","sequence":"first","affiliation":[{"name":"Division of Chemistry, School of Basic Sciences, Galgotias University","place":["Greater Noida, India"]},{"name":"Integral Bioscience Pvt. Ltd","place":["Noida, India"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Divya Bajpai","family":"Tripathy","sequence":"additional","affiliation":[{"name":"Division of Chemistry, School of Basic Sciences, Galgotias University","place":["Greater Noida, India"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dhananjay","family":"Pendharkar","sequence":"additional","affiliation":[{"name":"Integral Bioscience Pvt. Ltd","place":["Noida, India"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vijay Kumar","family":"Sharma","sequence":"additional","affiliation":[{"name":"Integral Bioscience Pvt. Ltd","place":["Noida, India"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gaurav","family":"Sharma","sequence":"additional","affiliation":[{"name":"Integral Bioscience Pvt. Ltd","place":["Noida, India"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2025,3,10]]},"reference":[{"volume-title":"StatPearls","author":"Wilson TK","key":"e_1_3_5_2_1","unstructured":"Wilson TK, Tripp, J, Buspirone. StatPearls. Treasure Island (FL): Study Guide from StatPearls Publishing. PMID: 30285372."},{"key":"e_1_3_5_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.brainres.2012.04.032"},{"key":"e_1_3_5_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2015.01.050"},{"key":"e_1_3_5_5_1","volume-title":"The Recovery Village","author":"Deveney R","year":"2020","unstructured":"Deveney R, Andrew Proulx MD, editor. Buspirone: overview and benefits. The Recovery Village; 2020. https:\/\/www.therecoveryvillage.com\/treatment-program\/addiction-medications\/buspirone\/#."},{"key":"e_1_3_5_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrd3473"},{"key":"e_1_3_5_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tips.2006.04.002"},{"key":"e_1_3_5_8_1","volume-title":"Buspirone (BuSpar) Manufacturing Plant Project Report 2024: Industry Trends, Plant Setup, Machinery, Raw Materials, Investment Opportunities, Cost, and Revenue","author":"IMARC Group","year":"2024","unstructured":"IMARC Group. Buspirone (BuSpar) Manufacturing Plant Project Report 2024: Industry Trends, Plant Setup, Machinery, Raw Materials, Investment Opportunities, Cost, and Revenue; 2024. Report ID: SR112024A12496. https:\/\/www.imarcgroup.com\/buspirone-manufacturing-plant-project-report."},{"key":"e_1_3_5_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2016.09.018"},{"key":"e_1_3_5_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsxm.2021.05.016"},{"key":"e_1_3_5_11_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm8101640"},{"key":"e_1_3_5_12_1","unstructured":"Credevo. Pharmaceutical product feasibility; 2024. https:\/\/www.credevo.com\/articles\/pharmaceutical-product-feasibility."},{"key":"e_1_3_5_13_1","unstructured":"Choudhary A. Pilot plant scale-up considerations for solids liquid orals semi-solids and relevant documentation; 2024. Pharmaguideline. https:\/\/www.pharmaguideline.com\/pilot-plant-scale-up-considerations"},{"key":"e_1_3_5_14_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.oprd.0c00247"},{"key":"e_1_3_5_15_1","doi-asserted-by":"publisher","DOI":"10.1021\/op300144g"},{"key":"e_1_3_5_16_1","doi-asserted-by":"publisher","DOI":"10.3949\/ccjm.87a.ccc016"},{"key":"e_1_3_5_17_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-46067-7"},{"key":"e_1_3_5_18_1","unstructured":"Yasgur BS. Shortage of antianxiety drug leaves patients in the Lurch; 2019. Psychology Today. https:\/\/www.psychologytoday.com\/us\/articles\/shortage-of-antianxiety-drug-leaves-patients-in-the-lurch"},{"key":"e_1_3_5_19_1","doi-asserted-by":"publisher","DOI":"10.3390\/molecules27020488"},{"key":"e_1_3_5_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.arabjc.2022.104101"},{"key":"e_1_3_5_21_1","doi-asserted-by":"publisher","DOI":"10.3390\/cimb45020093"},{"key":"e_1_3_5_22_1","doi-asserted-by":"publisher","DOI":"10.1080\/10406638.2022.2138922"},{"key":"e_1_3_5_23_1","unstructured":"APIFDF Analytics. Curated data driven trade insights; 2024. https:\/\/www.apifdf.com\/request-demo. ."},{"key":"e_1_3_5_24_1","unstructured":"Wise Guy Reports. Global Buspirone Hydrochloride Market Research Report; 2024."},{"key":"e_1_3_5_25_1","first-page":"79","article-title":"Conformational analysis and pharmacophore design for selected 1-(2-Pyrimidinyl)piperazine derivatives with sedative-hypnotic activity","volume":"58","author":"Bronowska A","year":"2001","unstructured":"Bronowska A, Le\u015b A, Mazgajska M, et\u00a0al. Conformational analysis and pharmacophore design for selected 1-(2-Pyrimidinyl)piperazine derivatives with sedative-hypnotic activity. Acta Pol Pharm Drug Res. 2001;58:79\u201386.","journal-title":"Acta Pol Pharm Drug Res"},{"key":"e_1_3_5_26_1","doi-asserted-by":"publisher","DOI":"10.2165\/00023210-199402030-00007"},{"key":"e_1_3_5_27_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm00094a020"},{"key":"e_1_3_5_28_1","doi-asserted-by":"publisher","DOI":"10.1248\/cpb.39.2288"},{"key":"e_1_3_5_29_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm00391a003"},{"key":"e_1_3_5_30_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm00129a014"},{"key":"e_1_3_5_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/0006-2952(80)90516-0"},{"key":"e_1_3_5_32_1","doi-asserted-by":"publisher","DOI":"10.1002\/jhet.5550450312"},{"key":"e_1_3_5_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2012.09.038"},{"key":"e_1_3_5_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2015.06.038"},{"key":"e_1_3_5_35_1","unstructured":"The Insight Partners. Buspirone Market Report; 2023. https:\/\/www.theinsightpartners.com\/reports\/buspirone-market"},{"key":"e_1_3_5_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2016.04.008"},{"key":"e_1_3_5_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2016.03.020"},{"key":"e_1_3_5_38_1","doi-asserted-by":"publisher","DOI":"10.1135\/cccc19902304"},{"key":"e_1_3_5_39_1","doi-asserted-by":"crossref","unstructured":"Duncton MA Roffey JR Hamlyn RJ et al. (2006). Parallel synthesis of N-arylpiperazines using polymer-assisted reactions. Tetrahedron Letters. 2016;47(15):2549\u20132552.","DOI":"10.1016\/j.tetlet.2006.02.047"},{"key":"e_1_3_5_40_1","volume-title":"CN104803923A \u2013 Synthetic method of piperazinyl pyrimidine intermediate","author":"China National Intellectual Property Administration","year":"2015","unstructured":"China National Intellectual Property Administration. CN104803923A \u2013 Synthetic method of piperazinyl pyrimidine intermediate; 2015."},{"key":"e_1_3_5_41_1","doi-asserted-by":"publisher","DOI":"10.1021\/op200097d"},{"issue":"12","key":"e_1_3_5_42_1","first-page":"1584","article-title":"Improved synthesis of piperazine-containing pyrimidines for use in the production of anxiolytic agents","volume":"49","author":"Chen L","year":"2019","unstructured":"Chen L, et\u00a0al. Improved synthesis of piperazine-containing pyrimidines for use in the production of anxiolytic agents. Synth Commun. 2019;49(12):1584\u20131594.","journal-title":"Synth Commun"},{"key":"e_1_3_5_43_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.accounts.7b00419"},{"key":"e_1_3_5_44_1","doi-asserted-by":"publisher","DOI":"10.3390\/su131810051"},{"key":"e_1_3_5_45_1","volume-title":"Guideline for good manufacturing practice","author":"ICH","year":"2021","unstructured":"ICH. Guideline for good manufacturing practice. International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use; 2021, Geneva, Switzerland."},{"key":"e_1_3_5_46_1","volume-title":"Q-8(R2)-ICH: guideline for good manufacturing practice","author":"ICH","year":"2009","unstructured":"ICH. Q-8(R2)-ICH: guideline for good manufacturing practice. International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use; 2009, Geneva, Switzerland."},{"issue":"7","key":"e_1_3_5_47_1","first-page":"1854","article-title":"Continuous flow chemistry for green pharmaceutical synthesis","volume":"22","author":"Lee J","year":"2020","unstructured":"Lee J, et\u00a0al. Continuous flow chemistry for green pharmaceutical synthesis. Green Chem. 2020;22(7):1854\u20131865.","journal-title":"Green Chem"}],"container-title":["Drug Development and Industrial Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/03639045.2025.2473505","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,31]],"date-time":"2025-03-31T23:56:05Z","timestamp":1743465365000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/03639045.2025.2473505"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,10]]},"references-count":46,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4,3]]}},"alternative-id":["10.1080\/03639045.2025.2473505"],"URL":"https:\/\/doi.org\/10.1080\/03639045.2025.2473505","relation":{},"ISSN":["0363-9045","1520-5762"],"issn-type":[{"type":"print","value":"0363-9045"},{"type":"electronic","value":"1520-5762"}],"subject":[],"published":{"date-parts":[[2025,3,10]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iddi20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iddi20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2024-10-17","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-02-18","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-02-22","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-03-10","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}